EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging landscape of KRAS inhibitors in cancer treatment

Jakob M Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi S Patel, Ferran Fece de la Cruz, Doga C Gulhan, Ryan B Corcoran

Cancer Cell · 2026-03 · 44 (3) · 471-497

DOI: 10.1016/j.ccell.2026.01.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-03. Verfasst von Jakob M Riedl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Oncology, Department of…. Hauptthemen laut MEDLINE: Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Stand up to Cancer, American Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alterations in KRAS, NRAS, and HRAS occur in roughly 20% of patients with cancer, making RAS one of the most intensively studied oncogenic targets. The discovery of mutant-selective KRASG12C inhibitors has provided a proof-of-concept for RAS-directed therapies, heralding a new era in the treatment of RAS-driven cancers. Yet, the efficacy of first-generation KRASG12C inhibitors is limited by the rapid emergence of resistance. Novel classes of (K)RAS inhibitors with distinct mechanisms of action and broader target coverage hold promise to overcome resistance and extend the benefits of RAS-targeted therapies to a wider patient population. In this review, we summarize clinical evidence for KRASG12C inhibitors across tumor types and delineate key mechanisms of resistance. We further discuss the rapidly evolving landscape of next-generation (K)RAS inhibitors, with particular emphasis on their target selectivity, mechanisms of action, preliminary clinical efficacy, and the therapeutic opportunities and challenges inherent to each class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProto-Oncogene Proteins p21(ras)Antineoplastic AgentsProtein Kinase InhibitorsHumansDrug Resistance, NeoplasmMutationAnimalsMolecular Targeted Therapy

Stichwörter der Autor:innen

KRASKRAS G12CKRAS inhibitorcolorectal cancerdrug resistancenon-small cell lung cancerpancreatic cancer

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: rbcorcoran@mgb.org.

Förderung

  • Austrian Science Fund
  • Stand up to Cancer
  • American Society of Clinical Oncology
  • Conquer Cancer Foundation

Zitieren

APA

Riedl, J. M., Matsubara, H., McNeil, R., Patel, P. S., Fece de la Cruz, F., Gulhan, D. C., & Corcoran, R. B. (2026). Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell, 44(3), 471-497. https://doi.org/10.1016/j.ccell.2026.01.001

Vancouver

Riedl JM, Matsubara H, McNeil R, Patel PS, Fece de la Cruz F, Gulhan DC, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026;44(3):471-497. doi:10.1016/j.ccell.2026.01.001

BibTeX
@article{Riedl2026,
  author = {Riedl, Jakob M and Matsubara, Hiroyuki and McNeil, Reid and Patel, Parasvi S and Fece de la Cruz, Ferran and Gulhan, Doga C and Corcoran, Ryan B},
  title = {Emerging landscape of KRAS inhibitors in cancer treatment},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {471--497},
  doi = {10.1016/j.ccell.2026.01.001}
}
Kostenlos starten →